The quinoxaline nonnucleoside RT inhibitor (NNRTI) (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-dihydroquinoxaline-2(1H)-thione (HBY 097) was used to select for drug-resistant HIV-1 variants in vitro. The viruses first developed mutations affecting the NNRTIbinding pocket, and five of six strains displayed the RT G190--E substitution, which is characteristic for HIV-1 resistance against quinoxalines. In one variant, a new mutant (G190->Q) most likely evolved from preexisting G190->E mutants. The negative charge introduced by the G190->E substitution was maintained at that site of the pocket by simultaneous selection for V179--D together with G190--Q. After continued exposure to the drug, mutations at positions so far known to be specific for resistance against nucleoside RT inhibitors (NRTIs) (L74-*V/I and V75->L/I) were consistently detected in all cultures. The inhibitory activities of the cellular conversion product of 2',3'-dideoxyinosine (ddl, didanosine), 2',3'-dideoxyadenosine (ddA) and of 2',3'-didehydro-3'-deoxythymidine (d4T, stavudine) against these late-passage viruses were shown to be enhanced with the L74->V/I RT mutant virus as compared with the wild-type (wt) HIV-1MN isolate. Clonal analysis proved linkage of the codon 74 and codon 75 mutations to the NNRTI-specific mutations in all RT gene fragments. The nonnucleoside-and nucleoside-resistance mutation sites are separated by approximately 35 A. We propose that the two sites "communicate" through the template-primer which is situated in the DNAbinding cleft between these two sites. Quinoxalines cause high selective pressure on HIV-1 replication in vitro; however, the implication of these findings for the treatment of infection has yet to be determined. Viral resistance against both nucleoside reverse transcriptase (RT) inhibitors (NRTIs) and nonnucleoside RT inhibitors (NNRTIs) of human immunodeficiency virus type 1 (HIV-1) replication develops in vitro (cell culture) and in vivo (patients). NRTIs select for RT amino acid substitutions at positions that can be allocated to different structural elements of the protein in the range of residue numbers 41-219 (1-5). A molecular mechanism for some alterations can be assumed on the basis of the RT crystal structure (6-8). In contrast, NNRTI-specific substitutions map exclusively to those protein secondary structure elements that together form a lipophilic pocket within the palm domain of the p66 RT subunit. All NNRTIs are believed to bind to this region, and mutations selected for by these drugs usually
L74->V/I RT mutant virus as compared with the wild-type (wt) HIV-1MN isolate. Clonal analysis proved linkage of the codon 74 and codon 75 mutations to the NNRTI-specific mutations in all RT gene fragments. The nonnucleoside-and nucleoside-resistance mutation sites are separated by approximately 35 A. We propose that the two sites "communicate" through the template-primer which is situated in the DNAbinding cleft between these two sites. Quinoxalines cause high selective pressure on HIV-1 replication in vitro; however, the implication of these findings for the treatment of infection has yet to be determined. Viral resistance against both nucleoside reverse transcriptase (RT) inhibitors (NRTIs) and nonnucleoside RT inhibitors (NNRTIs) of human immunodeficiency virus type 1 (HIV-1) replication develops in vitro (cell culture) and in vivo (patients). NRTIs select for RT amino acid substitutions at positions that can be allocated to different structural elements of the protein in the range of residue numbers 41-219 (1) (2) (3) (4) (5) . A molecular mechanism for some alterations can be assumed on the basis of the RT crystal structure (6) (7) (8) . In contrast, NNRTI-specific substitutions map exclusively to those protein secondary structure elements that together form a lipophilic pocket within the palm domain of the p66 RT subunit. All NNRTIs are believed to bind to this region, and mutations selected for by these drugs usually
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. occur in the segments composed of RT amino acids 98-108, 179-190, and 230-236 (9) (10) (11) (12) (13) (14) (15) (16) . Especially the Y181-*C RT mutant appears with many chemically distinct compounds, including different NNRTI combinations (12) .
6-Chloro-3,3-dimethyl-4-(isopropenyloxycarbonyl)-3,4-dihydroquinoxaline-2(1H)-thione (S-2720) and other quinoxalines select for a characteristic G190-E RT mutant when drug-resistant viruses are generated in cell culture (17, 18) . However, the interesting feature of the latter mutant is a clearly decreased enzymatic activity of the resulting recombinant G190-*E enzyme in vitro (17, 19, 24) .
We report here the results of in vitro dose-escalation experiments with the clinical candidate (S)-4-isopropoxycarbonyl-6-methoxy-3-methylthiomethyl-3,4-dihydroquinoxaline- The nonnucleoside inhibitor binding pocket is close to the DNA-binding cleft and contains structural elements in common with the "primer grip" (7, 20, 21) . Mutations at position 190 could distort the conformation of the primer grip or other nearby DNA-binding elements, and the NRTI-specific mutations (L74--V/I and V75-*L/I) possibly compensate for the changes across the DNA-binding cleft.
Abbreviations: HIV-1, human immunodeficiency virus type 1; RT, reverse transcriptase; NNRTIs, nonnucleoside inhibitors of the HIV-1 RT; HBY 097, (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-dihydroquinoxaline-2(1H)-thione; NRTIs, nucleoside RT inhibitors; ddl, didanosine, 2',3'-dideoxyinosine; ddA, 2',3'-dideoxyadenosine; d4T, stavudine, 2',3'-didehydro-3'-deoxythymidine; AZT, zidovudine, 3'-azido-3'-deoxythymidine; wt, wild type.
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MATERIALS AND METHODS
Compounds. HBY 097 and S-2720 were synthesized as described (17, 22) . 3'-Azido-3'-deoxythymidine (zidovudine, AZT) was obtained from Burroughs Wellcome. 2',3'-Dideoxyade- (17) . A dose-escalation protocol was used, starting with HBY 097 at 1 ng/ml at passage 1.
Population-Based Sequence Determination of the HIV-1 RT Gene. Purified total cellular DNA from infected cell lysates was eluted in 10 mM Tris-HCI/1 mM EDTA, pH 8.0. A 0.5-,ug sample of DNA was used for a first PCR with primers JA99 and RIT137 (23 (17) . Recombinant HIV-1 RT fused C-terminally to the Escherichia coli maltose-binding protein (MBP) was obtained and purified upon induction of the Ptac promoter as described (17, 19) . RT preparations were up to 90-95% pure, as judged by examination of stained gels.
For determination of enzyme IC50 values, dilutions of compounds in dimethyl sulfoxide were incubated with scintillation proximity (SPA) reagents (Amersham). RNA-dependent DNA synthesis with a heteropolymeric primer/template (5'-GTCAT-AGCTGTTTCCTG-3'/5'-UCUGCGGCAUUGCGAGCGG-AUAACAAUUUCACACAGGAAACAGCUAUGAC-3') was allowed to occur for 20 min at 37°C in the presence of [3H]dTTP. Enzymes were diluted in 20 mM Tris-HCl, pH 7.2, and inhibitor solutions were tested in duplicate.
RESULTS

Analysis of the HIV-1 RT Gene During in Vitro Selection for
Resistance of HIV-IMN Against HBY 097. H9 cells were infected with HIV-1MN and cultured in the presence of HBY 097. NNRTI-specific mutations were detected in all but one culture at passage 5 ( Fig. 1) , and the G190-E RT was already predominant in strains B and E. At passages 12 and 18 the Y181--C mutants had disappeared from cultures A and F, respectively, and five of six cultures displayed G190->E RTs. In addition, lineage A was a mixture of G190->Q/G190->E mutants, accompanied by a V179->D substitution, leaving V179--D/G190-*Q RT changes at passage 20. In culture C, an accumulation of NNRTI-specific mutations was observed, and in cultures B and D a V189-l (GTA -> ATA) change appeared, which was sustained to passage 30.
Evolutionary changes continued in the RT gene during later passages, affecting the fingers domain of the RT molecule. Surprisingly, mutations in codons 74 and 75 (L74--V/I, V75->L/I) were detected in all cultures.
Determination of Mutations in Cloned Proviral RT Genes. At first, we were interested in the passage 12 viruses of culture A. There was a mixture of two mutations in RT codon 190, together with an alteration in position 179 (Fig. 1) . The majority (13/18) of the clones carried a V179->D/G190-Q combination, and 0 of 18 RT genes harbored V179->D along with G190-*E. Likewise, there were no (0/18) V179--D single mutants and only 2 of 18 clones encoded the G190-Q RT in the absence of V179->D.
In the late-passage viruses of cultures A, D, E, and F L74->V, L74-I, V75--L or V75->I changes were always linked to a codon 190 mutation (26/26 clones). Although there were mixtures of mutations observed in both codon 74 and 75 in cultures B, C, D, and F (Fig. 1) tFold concentration compared with RT-1 MN is given in parentheses.
tRelative to the RT-1 MN wt enzyme. merase activity (24) . In the same study, protein folding of the recombinant enzyme was shown to be impaired through the G190->E substitution.
One virus strain developed an accumulation of NNRTIspecific mutations, giving rise to recombinant RTs which did not yield soluble protein upon expression in E. coli (L100->I/ K103->N/Y181---C/G190->A). Since the same was observed with a L100-*I/K103->N mutant RT, we conclude that this combination of mutations may result in a phenotype similar to that seen with the G190--E RTs. Consistent with our data, Boyer et al. (25) recently described a close relationship of low solubility and decreased enzymatic activity of certain mutated HIV-1 RTs.
A V179->D/G190->Q [supposed mutations GGA (Gly) -> GAA (Glu) --CAA (Gln)] mutant virus strain was observed in only one of six cultures. In this case an escape mechanism from the weakly active G190-*E RT was expected, since a G190->Q single-mutant RT was previously shown both to be resistant to inhibition by quinoxalines and to display wt polymerase activity (19) . Interestingly, the V179-*D/G190->Q recombinant RT also displayed a clearly decreased polymerase activity (Table 1) , and the G190--Q single mutants did not take over in lineage A or in one of the other cultures. These findings argue in favor of an important role for the appearance of V179--D and G190-Q at the same time.
The V179 and G190 residues are located in the 139-1310 hairpin, which forms part of the NNRTI-binding pocket (20, 21) (Fig. 2) . V179->D and G190--E/Q RT mutants would result in changes of local electrostatic potential and would most likely lead to steric hindrance in binding NNRTIs. The mutations at both of these positions result in increased steric bulk and reduction of pocket size, possibly explaining the observation that the G190->E/Q RT mutants confer highlevel resistance to a variety of NNRTIs (this study and ref. 19) .
The most surprising result that comes from this study is the consistent occurrence of NRTI-specific mutations in NNRTItreated virus strains (RT L74->V/I and RT V75->L/I). These additional changes always developed after changes in position 190 were already present in the RT. We did not detect any of the NRTI-specific amino acid changes when we propagated HIV-1MN on H9 cells in the presence of the pyridinone class NNRTI L-697661 for a total of 30 passages (data not shown).
The L74 and L75 residues are located in the 134 strand, which is a component of the fingers subdomain. These residues in the p66 subunit are about 35 A distant from residues V179 and G190 in the NNRTI-binding pocket, with the template-primer located in between (Fig. 2) . Since a mutation in the RT gene leads to alterations in both the p66 and p51 subunits, it is possible that the substitutions at amino acid positions 74 and 75 in pSi could be important. However, these positions in p51
are at a large distance from the polymerase active site in the RT heterodimer and the changes in pSi are less likely to be involved. Observation of NRTI-specific mutations in the presence of NNRTI-treated virus strains suggests that potential distortion of the conformation of the primer grip or the 139-1310 hairpin by the NNRTI mutations may be compensated by NRTI-specific mutations so as to accommodate the template-primer. Previous studies (8) demonstrated that mutations that confer resistance to dideoxynucleoside analogues, including L74--V, apparently lead to changes at the active site through changing the conformation or position of the template-primer. Analyses of foscarnet-resistant HIV-1 RT also suggest that mutations across the DNA-binding cleft may lead to alterations in binding of foscarnet at the polymerase active site, again "communicating" from the site of mutation through the template-primer (26) . We therefore propose a connection between quinoxaline-specific mutations that impair polymerase activity and the NRTI mutations that occur in the fingers subdomain. As a result of the NNRTI-induced interactions between the lipophilic pocket and consequent distortion of the primer grip, NRTI mutations may partly compensate for altered interactions of HIV-1 RT with templateprimer.
A 2.4-fold increase in IC50 was seen with the 2',3'-dideoxyinosine (didanosine, ddI) conversion product ddA and the L74->V-containing multiple RT mutant virus that was obtained with HBY 097 (Table 2 ). The fact that only one-third (4/13 clones) of this provirus population in culture D specified L74-*V RTs may account for the difference from the 8.3-fold increase in IC50 observed with ddl and a L74-V RT virus construct (2) . An influence of the G190->E substitution with respect to the ddA/ddl-resistant phenotype exerted by the L74--V alteration could also be assumed. V75->I-containing multiple mutant RTs were recently found to be associated with drug-resistance in a few HIV-1 infected patients who underwent NRTI combination therapy with AZT and ddl or AZT and 2',3'-dideoxycytidine (ddC) (27, 28 The most likely explanation for the selective advantage of the mutations in codon 74 and codon 75 is an enhanced polymerase activity of the resulting enzymes, as observed with the V75->I/G190->E RT (Table 1) . At this point it could be speculated that, i.e., the nature of the enzyme fusion used could affect the activity of certain recombinant RTs relative to wt. However, all of our numerous control mutants constructed and checked for polymerase activity behaved as expected from published data (Table 1 and refs. 17 and 19) .
The fact that both the L74-*V/I and V75->L/I changes always appeared after introduction of quinoxaline resistance serves as additional proof of a direct connection of these consecutive events, probably through a molecular mechanism as discussed above.
The data presented here provide a link between HIV-1 resistance against two types of compounds, which inhibit the HIV-1 RT and virus replication through different modes. Therefore, these findings seem at first sight to add just another factor of complexity to the field of resistance to RT inhibitors. However, it also becomes evident that the possibilities for HIV-1 to escape from the effects of carefully selected drugs may be limited. Combination chemotherapy on the level of RT inhibition could possibly make use of the fact that parallels exist in the mutational pathways followed by HIV-1 to become less sensitive to certain nucleoside analogues or quinoxalines.
